Assessing basophil functional measures during monoclonal anti-IgE therapy.
Assessing the impact of therapeutic interventions on the clinical and immunologic responses of allergic subjects is a topic of extensive investigation. Available approaches include the measurement of in vivo allergen challenge responses, serologic measures, or in vitro studies of cells that participate in the allergic reaction. Several decades of work support that measures of allergen responses of IgE-bearing peripheral blood basophils can reflect clinical expression of allergic disease. In the last decade, an immune-based therapy targeting IgE, omalizumab, has emerged as an adjunct treatment for a variety of allergic diseases. This monoclonal humanized IgG antibody specifically binds circulating IgE at a region in the Fc tail that prevents IgE attachment to high affinity IgE receptor (FcεRI) bearing cell types such as tissue mast cells and blood basophils. This review focuses on methods to monitor changes of basophil allergen reactivity with a focus on omalizumab therapy and the implications for clinical disease management.
John Hopkin's University, School of Medicine, USA. ssaini@jhmi.edu
Sarbjit S
SS
Saini
Donald W
DW
MacGlashan
D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001491:Basophils / Q000276:immunology*; D006801:Humans; D006967:Hypersensitivity / Q000097:blood / Q000276:immunology / Q000628:therapy*; D007073:Immunoglobulin E / Q000097:blood / Q000276:immunology*; D007159:Immunologic Tests; D007167:Immunotherapy / Q000379:methods*; D015166:Monitoring, Immunologic / Q000379:methods*; D000069444:Omalizumab; D011237:Predictive Value of Tests; D016896:Treatment Outcome
D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D007073:Immunoglobulin E